Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FISONS' OPTICROM 4% SOLUTION FOR OCCULAR ALLERGIES

Executive Summary

FISONS' OPTICROM 4% SOLUTION FOR OCCULAR ALLERGIES is the company's latest entry into its cromolyn sodium product line. On Oct. 10, the firm announced approval of the product for occular allergies. According to the FDA-approved labeling, Opticrom is "indicated in the treatment of certain allergic occular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis, vernal keratitis, and allergic keratoconjunctivitis. "The etiologic factors are unknown, but common airborne allergens and contact lenses have been implicated." The labeling adds that "symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required." Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement." The indication notes that if required corticosteroids may be used concomitantly. The cromolyn sodium eye drops are supplied as 10 ml bottles, the company noted. The drug is priced to whslrs.'s at $8 for a 10 ml bottle. Opticrom joins Fisons' cromolyn sodium products Intal, an inhalant for bronchialasthma and Nasalcrom, a nasal spray for the prevention and treatment of allergic rhinitis symptoms.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS007314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel